Does Biomarker Use in Oncology Improve Clinical Trial Failure Risk? A Large-scale Analysis.

Parker JL, Kuzulugil SS, Pereverzev K, Mac S, Lopes G, Shah Z, Weerasinghe A, Rubinger D, Falconi A,

Tuesday, February 23, 2021 - 17:00

Program News, Research

Students in Study — A pre-COVID photo of some of the students involved in the study. From right: **Rohan Tangri, Ashini Weerasinghe, Zain Shah, Kirill Pereverzev** and Stephen Mac.

Cancer Medicine, 2021; 10(6):1955-1963. › 10.1002/cam4.38732

Impact factor: 3·4

Application relevance: This study provides the first systematic statistical evidence that biomarkers clearly increase clinical trial success rates in three different indications in oncology. Also, exploratory biomarkers, long before they are properly validated, appear to improve success rates in oncology. This study supports early and aggressive adoption of biomarkers in oncology clinical trials.

More News from UTM

MBiotech at 25 Years

11/19/2024 - 12:33

A Quarter Century of Excellence: MBiotech 25 Years (2000-2025) | Scott Prosser stands at the main entrance of UTM

New digital health technology course introduces grad students to the world of digital health and entrepreneurship

03/19/2024 - 17:17

IMI Emerging Technology & AI Award

08/23/2023 - 15:01